Here are the 10-K annual reports from Sarepta Therapeutics,, Inc. (SRPT) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow SRPT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SRPT filings page.
Sarepta Therapeutics is a commercial-stage biopharma company focused on RNA-targeted drugs, siRNA therapies and gene therapies for rare neuromuscular diseases, led by Duchenne muscular dystrophy.
The company sells four approved Duchenne products—EXONDYS 51, VYONDYS 53, AMONDYS 45 and the gene therapy ELEVIDYS—and recorded $1,864.3 million in product net revenues for the year ended December 31, 2025, up from $1,788.0 million in 2024 and $1,144.9 million in 2023.
2025 brought significant challenges. Top-line results from the ESSENCE confirmatory trial for VYONDYS 53 and AMONDYS 45 did not meet the primary endpoint, and Sarepta plans further FDA discussions on their approval status. ELEVIDYS was temporarily suspended in the U.S. after serious safety events, later resuming only for ambulatory patients and gaining a boxed warning for acute liver injury and acute liver failure while the non-ambulatory indication was removed from labeling.
The FDA also placed a clinical hold on Sarepta’s LGMD gene therapy trials after a patient death, with SRP‑9003’s path now contingent on additional sirolimus data. At the same time, Sarepta entered a large siRNA collaboration with Arrowhead, paying a $500.0 million upfront fee plus substantial milestones and royalties, and continues to partner with Roche on ELEVIDYS ex-U.S. and with Catalent and Aldevron for manufacturing.